Progenity Sells Its Liquid Biopsy Technologies to Enumera Molecular

Progenity has sold its discovery-stage liquid biopsy technologies to newly formed Enumera Molecular, a life science tools company based in Ann Arbor, Mich., which intends to develop and commercialize them.

Progenity’s liquid biopsy technologies are designed to assess biomolecules. Enumera plans to develop a scalable biomolecule assessment platform for lower cost, rapid, clinical liquid biopsy tests.

The financial terms of the sale were not disclosed, but Progenity will receive an ownership stake in Enumera Molecular.

Progenity, which specializes in gastrointestinal health and oral biotherapeutics, is developing ingestible devices designed to provide precise drug delivery solutions and diagnostic sampling. The company is also rebranding itself as Biora Therapeutics.